Neurogene reaffirms Embolden data for 2H 2027, cash runway into Q1 2029
Neurogene's third-quarter update held its Rett syndrome gene therapy timeline steady while R&D spending and net loss both increased year over year.
SEC filing (8)
47 stories
Neurogene's third-quarter update held its Rett syndrome gene therapy timeline steady while R&D spending and net loss both increased year over year.
SEC filing (8)
The combination regimen is approved for muscle-invasive bladder cancer patients who cannot receive cisplatin-based chemotherapy, based on Phase III VOLGA trial results.
SEC filing
The FDA approved the once-weekly subcutaneous C5 inhibitor for AChR antibody-positive adult gMG, with the agency's review record dated 13 November 2026.
Drugs@FDA, SEC filing (3)
ORIC Pharmaceuticals plans a Phase 3 trial comparing enozertinib to osimertinib or afatinib in 1L EGFR atypical NSCLC, as FDA records confirm two prior osimertinib approvals.
FDA, SEC filing (3)
The agency's latest durvalumab approval covers muscle invasive bladder cancer, adding to its 2024 clearance in resectable lung cancer.
Drugs@FDA, FDA (3)
The dermatology company said Emrosi revenue climbed to $9.0 million while cash fell to $22.3 million, with the vendor dispute payout weighing on quarterly costs.
SEC filing (2)
The company also flagged a Phase 3 readout from partner AstraZeneca's rilvegostomig program in H2 2027 and said cash runway extends into 2029.
SEC filing
The company said topline interim results from its pivotal FORTIFI-HN01 study are expected in mid-2027, while cash on hand is projected to fund operations into the first half of 2029.
SEC filing (10)
The agency cleared capivasertib with abiraterone and prednisone for PTEN-deficient, androgen pathway modulation-naïve or -sensitive metastatic prostate cancer.
FDA (6)
The agency's May 28, 2026 approval covers adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer.
FDA (2)
Innate Pharma reported progress on its Nectin-4 ADC, lacutamab and monalizumab programs alongside a cash position of €96.8 million as of September 30, 2026.
SEC filing
The company signed a definitive deal to divest Prenatal Health to Labcorp for $210 million in cash plus inventory value, expected to close by early 2027, while nudging up full-year 2026 revenue guidance.
SEC filing
The regulatory filings follow an FDA submission in September 2026 and build on SAFFRON Phase III data showing a 45% cut in progression risk and nearly five months of added survival.
SEC filing (3)
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)
AstraZeneca delayed the Phase 3 trial's high-level data readout by roughly six months, citing the study's event-driven design.
SEC filing
The approval, announced October 27, 2026, triggers a $75 million milestone payment from AstraZeneca to Daiichi Sankyo and marks Enhertu's first EU nod in curative-intent early breast cancer.
SEC filing
AstraZeneca's Alexion unit said Ultomiris is now the first C5 complement inhibitor cleared in the US to cut proteinuria in adults with the rare kidney disease.
Drugs@FDA, SEC filing (2)
The October 20, 2026 deal gives Imunon equity, milestone payments up to $16.5 million, and royalties, while it keeps focus on its Phase 3 OVATION 3 trial.
SEC filing (5)
Former Sanofi CEO Hudson and Verily Health CFO Koppikar join as independent directors effective October 19, 2026, with board committee assignments and equity grants detailed in the filing.
SEC filing
Farrow, who serves as CFO and chief strategy officer of Tarsus Pharmaceuticals, joins Lisata's Audit Committee as the board expands to eight members.
SEC filing
The FDA approved a Type 5 new formulation or manufacturer submission for Breztri Aerosphere on October 8, 2026.
Drugs@FDA
The companies plan to start with a Phase III trial in first-line triple-negative breast cancer, per a filing dated October 2, 2026.
SEC filing
The application, based on the Phase III SAFFRON trial, targets patients who progressed on EGFR-TKI therapy with MET overexpression or amplification.
SEC filing (2)
Daly, former Catalyst Pharmaceuticals CEO, joins effective October 14, 2026, as the company prepares for a potential launch of its allergy drug Anaphylm.
SEC filing
The triple-combination inhaler becomes the first of its kind cleared in the EU for asthma patients 12 and older regardless of exacerbation history.
SEC filing
Both positive opinions came on September 21, 2026, based on Phase III trial data in generalised myasthenia gravis and HER2-positive early breast cancer.
SEC filing (2)
The regulator cleared a sixth supplement to Truqap's original approval, with an updated label issued the following day.
Drugs@FDA
Zhang, formerly Novartis International's Chief Commercial Officer, succeeds interim CEO Alan Bash, who returns to lead the CARVYKTI business.
SEC filing
The Phase III study of Etcamah plus palbociclib showed a numerical but not statistically significant PFS benefit in untreated advanced ER-positive breast cancer.
SEC filing
The agency cleared an efficacy supplement and a related labeling update for the lung cancer drug osimertinib on the same day.
Drugs@FDA (2)
The approval covers Etcamah combined with a CDK4/6 inhibitor for first-line advanced HR-positive, HER2-negative breast cancer patients who develop an ESR1 mutation.
SEC filing
New NDA filing data shows Etcamah is a 75 mg film-coated tablet, approved September 4, 2026, alongside FDA's public announcement.
FDA press release, Drugs@FDA (2)